New biopharma CMO for Singapore

Manufacturing plant to include mammalian bioreactor trains

A CMO in Singapore manufacturing commercial biopharmaceuticals is the result of a partnership between two biopharmaceutical companies. Lonza, a Swiss chemical and biotechnology company, and Bio*One Capital, an Asian biomedical sciences investment management company, have signed a joint venture term sheet to establish the new organization. The Singapore-based plant will include four mammalian bioreactor trains, each with a capacity of 1000–20000 L.

The plant will be developed in two phases. Construction of the plant shell in the first phase will commence at the end of this year. The final build-out of the facility will be completed within 24 months of the completion of the plant shell in line with customer commitments.

The project capitalizes on Singapore's strengths in process development and clinical manufacturing of biopharmaceuticals, as well as the country's reputable capabilities in GMP manufacturing of bulk actives for global pharmaceutical companies.

lonza.com